Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2018
NCT03508921
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction | Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 4)

Infections (Phase 4)

Urinary Bladder, Overactive (Phase 4)

Urinary Tract Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 7